| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Edward C Suarez, K Ranga R Krishna. The relation of free plasma tryptophan to anger, hostility, and aggression in a nonpatient sample of adult men and women. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine. vol 31. issue 3. 2006-10-31. PMID:16700639. |
dysregulation of central nervous system serotonergic (5-ht) activity is implicated in behavioral states and psychological traits associated with depression and aggression, with some studies suggesting possible gender-related differences. |
2006-10-31 |
2023-08-12 |
Not clear |
| Iu O Fedotova, N A Platonova, N S Saprono. [8-OH-DPAT modulates expression of 5-HT(1A)/5-HT(2A), 17beta-estradiol receptor mRNAs in ovariectomized rats in Porsolt test]. Eksperimental'naia i klinicheskaia farmakologiia. vol 69. issue 3. 2006-09-25. PMID:16878502. |
the data obtained indicate a close interaction of the ovary hormonal and serotonergic systems of the brain in mechanisms of depression. |
2006-09-25 |
2023-08-12 |
rat |
| Adrienne E Dorr, Guy Debonne. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. The Journal of pharmacology and experimental therapeutics. vol 318. issue 2. 2006-08-31. PMID:16690723. |
serotonergic [5-hydroxytryptamine (5-ht, serotonin)] and noradrenergic [norepinephrine (ne)] systems are involved in the pathophysiology of depression and in the mechanisms of action of antidepressants. |
2006-08-31 |
2023-08-12 |
Not clear |
| Robert A Whittington, László Virá. Isoflurane decreases extracellular serotonin in the mouse hippocampus. Anesthesia and analgesia. vol 103. issue 1. 2006-08-16. PMID:16790633. |
furthermore, alterations in serotonergic neurotransmission in the hippocampus have been linked to depression and anxiety as well as to changes in arousal and cognition. |
2006-08-16 |
2023-08-12 |
mouse |
| Madhukar H Trived. Major depressive disorder: remission of associated symptoms. The Journal of clinical psychiatry. vol 67 Suppl 6. 2006-08-11. PMID:16848674. |
in the treatment of mdd, the noradrenergic, serotonergic, and dopaminergic neural pathways have been found to be affected by depression. |
2006-08-11 |
2023-08-12 |
Not clear |
| Norbert Müller, Markus J Schwar. Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert review of neurotherapeutics. vol 6. issue 7. 2006-08-09. PMID:16831116. |
in addition, the activation of the type 1 and the pro-inflammatory immune responses in major depression result in increased serotonin degradation and a serotonergic deficit. |
2006-08-09 |
2023-08-12 |
Not clear |
| Birgitte R Kornum, Pia Weikop, Arne Moller, Lars C B Ronn, Gitte M Knudsen, Susana Azna. Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. Brain research. vol 1073-1074. 2006-07-19. PMID:16426583. |
interactions between the serotonergic and cholinergic systems are known to occur and are believed to play a role in the mechanism underlying both major depression and alzheimer's disease. |
2006-07-19 |
2023-08-12 |
rat |
| Leo She. Alcohol and suicide: neurobiological and clinical aspects. TheScientificWorldJournal. vol 6. 2006-07-11. PMID:16799741. |
in individuals with comorbid depression and alcoholism, greater serotonergic impairment may be associated with higher risk of completed suicide. |
2006-07-11 |
2023-08-12 |
Not clear |
| David J Burn, Watcharee Tiangyou, Liesl M Allcock, Jill Davison, Patrick F Chinner. Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson's disease. Parkinsonism & related disorders. vol 12. issue 3. 2006-07-06. PMID:16459126. |
a genetic susceptibility to depression in pd, acting via the serotonergic system, has been suggested. |
2006-07-06 |
2023-08-12 |
Not clear |
| Marat G Uzbekov, Eduard Y Misionzhnik, Natella M Maximova, Olga P Vertogradov. Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants with different mechanisms of action. Human psychopharmacology. vol 21. issue 2. 2006-06-22. PMID:16342231. |
biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants with different mechanisms of action. |
2006-06-22 |
2023-08-12 |
Not clear |
| E B Binder, F Holsboe. Pharmacogenomics. Handbook of experimental pharmacology. issue 169. 2006-06-13. PMID:16594271. |
a number of studies have reported an influence of polymorphisms of genes mostly in the serotonergic pathway on the response to antidepressant drugs in patients suffering from depression. |
2006-06-13 |
2023-08-12 |
Not clear |
| Albert F G Leentjens, Bart Scholtissen, Fred W Vreeling, Frans R J Verhe. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 5. 2006-06-06. PMID:16205779. |
the serotonergic hypothesis for depression in parkinson's disease: an experimental approach. |
2006-06-06 |
2023-08-12 |
human |
| Albert F G Leentjens, Bart Scholtissen, Fred W Vreeling, Frans R J Verhe. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 5. 2006-06-06. PMID:16205779. |
the serotonergic hypothesis for depression in parkinson's disease (pd) states that the reduced cerebral serotonergic activity that occurs in pd constitutes a biological risk factor for depression. |
2006-06-06 |
2023-08-12 |
human |
| Albert F G Leentjens, Bart Scholtissen, Fred W Vreeling, Frans R J Verhe. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 5. 2006-06-06. PMID:16205779. |
the aim of our study was to assess the serotonergic hypothesis of depression in pd patients using an experimental approach. |
2006-06-06 |
2023-08-12 |
human |
| Albert F G Leentjens, Bart Scholtissen, Fred W Vreeling, Frans R J Verhe. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 5. 2006-06-06. PMID:16205779. |
we could find no evidence of a specific serotonergic vulnerability of pd patients for depression. |
2006-06-06 |
2023-08-12 |
human |
| Albert F G Leentjens, Bart Scholtissen, Fred W Vreeling, Frans R J Verhe. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 5. 2006-06-06. PMID:16205779. |
therefore, our results do not support the serotonergic hypothesis for depression in pd. |
2006-06-06 |
2023-08-12 |
human |
| Russel S Falck, Jichuan Wang, Robert G Carlson, Harvey A Siega. Prevalence and correlates of current depressive symptomatology among a community sample of MDMA users in Ohio. Addictive behaviors. vol 31. issue 1. 2006-06-05. PMID:15922511. |
research suggests that mdma can cause serotonin depletion as well as serotonergic neurodegradation that may result in depression among users of the drug. |
2006-06-05 |
2023-08-12 |
human |
| Shu Hasegawa, Kyoko Nishi, Arata Watanabe, David H Overstreet, Mirko Diksi. Brain 5-HT synthesis in the Flinders Sensitive Line rat model of depression: an autoradiographic study. Neurochemistry international. vol 48. issue 5. 2006-06-01. PMID:16427159. |
alterations of serotonin (5-ht) levels and serotonergic transmission have been associated with depression. |
2006-06-01 |
2023-08-12 |
rat |
| Shu Hasegawa, Kyoko Nishi, Arata Watanabe, David H Overstreet, Mirko Diksi. Brain 5-HT synthesis in the Flinders Sensitive Line rat model of depression: an autoradiographic study. Neurochemistry international. vol 48. issue 5. 2006-06-01. PMID:16427159. |
5-ht synthesis is an important factor of serotonergic neurotransmission that may also be altered in depression. |
2006-06-01 |
2023-08-12 |
rat |
| Pinhas N Dannon, Katherine Lowengrub, I Iancu, Moshe Kotle. Paroxetine in panic disorder: clinical management and long-term follow-up. Expert review of neurotherapeutics. vol 4. issue 2. 2006-04-25. PMID:15853560. |
paroxetine is unique among the selective serotonin reuptake inhibitors since, in addition to its effect on the cns serotonergic neurotransmission, it also has mild noradrenergic properties demonstrated to be effective in the treatment of anxiety disorders and depression. |
2006-04-25 |
2023-08-12 |
Not clear |